Connect your AI

Scholar Rock SRRK Investing Cash Flow

Investing Cash Flow at other companies

BiogenBIIB

-$209.5M-343%

Edgewise Therapeutics, Inc.EWTX

$2.43M-94.5%

PTC TherapeuticsPTCT

-$93.74M+49.2%

Dyne Therapeutics, Inc.DYN

-$2.39M-264%

Catalyst PharmaceuticalCPRX

-$27K—

Cogent Biosciences, Inc.COGT

-$36.46M-153%

Other financials

Income statement

Revenue-—

Operating income-$102.0M-32.3%

Net income-$105.5M-41.2%

EPS (diluted)-$0.83-23.9%

Balance sheet

Cash & equivalents$430.5M+212%

Total debt$205.7M+226%

Total equity$276.0M-11.6%

Total assets$535.3M+31.3%

Cash flow

Operating cash flow-$82.1M-4.4%

CapEx$68.0K-74.9%

Free cash flow-$82.2M-4.1%

Valuation

Market cap$5.67B+85.5%

Profitability

Operating margin-231.8%—

Net margin-236.9%—

FCF margin-309.1%—

Returns & leverage

Return on equity-138.9%+60.1pp

Debt / equity0.7×+0.5×

Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Scholar Rock's investing cash flow?: Scholar Rock (SRRK) reported investing cash flow of -$5.34M in Q1 2026.
How has Scholar Rock's investing cash flow changed year-over-year?: Scholar Rock's investing cash flow decreased by 115.4% year-over-year, from $34.55M to -$5.34M.
What is the long-term trend for Scholar Rock's investing cash flow?: Over 2 years (2021 to 2025), Scholar Rock's investing cash flow has grown at a 27.6% compound annual growth rate (CAGR), from $134.32M to $218.69M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.